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Abstract
The ability of innate immune cells to sense and respond to impending danger varies by anatomical location. The liver is
considered tolerogenic but is still capable of mounting a successful immune response to clear various infections. To
understand whether hepatic immune cells tune their response to different infectious challenges, we probed mononuclear
cells purified from human healthy and diseased livers with distinct pathogen-associated molecules. We discovered that only
the TLR8 agonist ssRNA40 selectively activated liver-resident innate immune cells to produce substantial quantities of IFN-c.
We identified CD161Bright mucosal-associated invariant T (MAIT) and CD56Bright NK cells as the responding liver-resident
innate immune cells. Their activation was not directly induced by the TLR8 agonist but was dependent on IL-12 and IL-18
production by ssRNA40-activated intrahepatic monocytes. Importantly, the ssRNA40-induced cytokine-dependent
activation of MAIT cells mirrored responses induced by bacteria, i.e., generating a selective production of high levels of
IFN-c, without the concomitant production of TNF-a or IL-17A. The intrahepatic IFN-c production could be detected not
only in healthy livers, but also in HBV- or HCV-infected livers. In conclusion, the human liver harbors a network of immune
cells able to modulate their immunological responses to different pathogen-associated molecules. Their ability to generate
a strong production of IFN-c upon stimulation with TLR8 agonist opens new therapeutic opportunities for the treatment of
diverse liver pathologies.
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Introduction
The liver is an essential organ at the center of carbohydrate,
lipid and protein metabolisms. It is crucial for clearing toxins and
pathogens that reach the circulatory compartment from the gut.
The liver is also home to abundant populations of innate immune
cells (monocytes, NK and NKT cells) whose local activation needs
to be tuned in order to avoid severe liver damage with life-
threatening consequences [1,2]. For these reasons, the immuno-
logical environment of the liver has been primarily associated with
tolerogenic features: abundance of immunosuppressive cytokines/
ligands (e.g., IL-10 or PD-L1), tolerance to LPS stimulation and
production of inhibitory enzymes (e.g., arginase) that can suppress
immune responses [3,4]. The ability of pathogens like HBV, HCV
and Plasmodium spp. to establish persistent infections in the liver
can be facilitated by such immunotolerant features.
The hypo-responsiveness of liver-resident immune cells is,
however, not absolute and selective triggers are known to activate
hepatic NK or CD56+ T cells: for example, liver-resident iNKT
cells are activated in mice infected with Borrelia burgdorferi [5].
Using human immune cells purified from a donor liver for
transplant, it was also shown that while Toll-like receptor 4/TLR4
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and TLR2 agonists triggered a tolerogenic response and prefer-
ential IL-10 production, a TLR3 agonist activated hepatic NK
cells through IL-18-mediated stimulation [6].
The difficulty in obtaining a substantial number of intrahepatic
human cells has precluded a comprehensive analysis of the signals
necessary to activate liver immunity. Furthermore, there is a
general problem of translating murine findings to the human liver.
The vast population of liver-resident T cells expressing NK
markers are mostly composed by MR1-restricted mucosal-
associated invariant T (MAIT) cells in humans and not by the
classical CD1d-restricted NKT cells, which are abundant in mice
[7]. Thus, studies on human hepatic immune cells are crucial.
Utilizing intrasinusoidal samples obtained during the procedure
preceding living-donor liver transplantation, we characterized the
requirements for selective activation of human intrahepatic
immune cells and the cellular subsets responsible for inducing a
potent immune response in the human liver microenvironment.
Results
Selective stimulation of liver intrasinusoidal cells by a
TLR8 agonist
To test whether liver intrasinusoidal cells can be differentially
activated by various pathogen-associated molecules, mononuclear
cells purified from healthy liver grafts preceding living-donor liver
transplantations (called liver-derived cells/LDCs) were stimulated
with TLR agonist 1/2, 2, 2/6, 3, 4, 5, 7, 8, or 9 (respectively
Pam3CSK4, HKLM, FSL-1, poly(I:C), LPS, flagellin, imiquimod,
ssRNA40, or CpG ODN2216) or anti-CD3/CD28-coupled beads
(TCR) as a control. We used TLR agonists at the concentration
that triggered maximal activation in PBMCs (not shown). After
18 hours of incubation, supernatants were collected and the
concentrations of antiviral (IFN-a, IFN- c), pro-inflammatory (IL-
1b, IL-6, IL-17A, TNF-a) and immunosuppressive (IL-10)
cytokines were measured. The purity and cell composition of
LDCs were recently described in detail [8]. For clarity, the
differential composition of lymphocytes and of monocytes and
dendritic cells/DCs obtained from the liver (n = 6) or peripheral
blood (n= 7) of age-matched healthy subjects are shown again in
Fig. 1A. Liver-derived lymphocytes are enriched in CD56Bright
NK and T cells expressing NK markers CD56 and CD161 which
are mainly mucosal-associated invariant T (MAIT) cells [8]. The
frequency of different monocyte subsets (CD14++CD162,
CD14+CD16+ and CD14dimCD16+) and of DCs were in contrast
similar in LDCs and PBMCs.
Fig. 1B shows the total production of IFN-a, IFN-c, IL1b, IL-6,
IL-10, TNF-a obtained in PBMCs of 5 healthy subjects and LDCs
from 9 healthy liver donors (matched for age). The tested TLR
agonists activated higher production of cytokines in PBMCs than
LDCs with the single notable exception of the TLR8 agonist
ssRNA40. Analysis of the single cytokines produced in ssRNA40-
activated LDCs showed a very high quantity of IFN-c, followed by
TNF-a and IL-1b (Fig. 1C). IFN-c quantity produced by
ssRNA40-activated LDCs (,5000 pg/mL) was higher than the
IFN-c triggered by anti-CD3/CD28-coupled beads (,3000 pg/
mL) and by the other TLR agonists (,500 pg/mL) (Fig. 1C and
1D). ssRNA40-activated LDCs also produced high quantities of
IL-1b and TNF-a, but the differences between LDCs and PBMCs
were not as dramatic as that observed for IFN-c: on average 27
times higher in LDCs than PBMCs (Fig. 1C and 1D). The TLR4
agonist LPS elicited also a high production of cytokines in LDCs
(Fig. 1B). The pro-inflammatory IL-1b, IL-6 and TNF-a and the
immunoregulatory IL-10 cytokines were the most highly produced
with levels similar between PBMCs and LDCs (IL-6, TNF-a, IL-
10) or higher in PBMCs than LDCs (IL-1b) (Fig. 1C). IFN-a was
detectable only at low concentrations (,63 pg/mL) upon TLR9
activation with production higher in PBMCs than in LDCs (not
shown). TLR agonists did not induce production of IL-17A, which
was only detectable at low levels in LDCs and PBMCs (,57 and
,124 pg/mL, respectively) upon TCR stimulation (not shown).
MAIT and CD56Bright NK cells are the main IFN-c-
producing sources within ssRNA40-activated LDCs
We next characterized the cellular component responsible for
the high IFN-c, TNF-a and IL-1b production in LDCs after
ssRNA40 stimulation. Visualization of cytokine-producing cells
was performed by intracellular staining, adding the protein
transport inhibitor brefeldin A either immediately or only in the
last 5 hours of the stimulation. IFN-c-producing cells within both
the CD3+ and CD32 lymphocyte populations were visualized only
with the addition of brefeldin A in the final 5 hours as the
overnight presence of brefeldin A resulted in a diminished
response (not shown). Characterization of the cellular composition
of IFN-c producers based on NK- and T-cell subsets (see tree
diagram in Fig. 2A) revealed that despite different frequencies in
different individual samples (pie charts in Fig. 2A), three lymphocyte
populations were responsible for the majority of IFN-c production
upon ssRNA40 stimulation: CD32CD56+CD162 (CD56Bright NK
or NKBright cells), CD3+cd2CD42CD161+Valpha 7.2+ (MAIT
cells) and to a lesser extent, CD3+cd+ cells (cdT cells). CD56Dim NK
(NKDim cells) and conventional T cells were, in contrast, weakly
activated (Fig. 2A and 2B). Importantly, as shown in the dot plots of
a representative sample in Fig. 2B, ssRNA40-activated lymphocytes
produced only IFN-c, while TNF-a and IL-1b were produced by
activated monocytes (Fig. 2B).
The higher production of IFN-c by ssRNA40-activated LDCs
in comparison to PBMCs can be explained by the preferential liver
compartmentalization of MAIT and NKBright cells (Fig. 2C first
panel). However we also tested whether liver-derived MAIT and
NKBright cells were more efficiently activated than blood-derived
cells. As shown in Fig. 2C, the frequency of IFN-c-producing
MAIT or NKBright subset within the total population present in
Author Summary
The ability of human pathogens, like HBV, HCV or
Plasmodium spp. to infect the liver might be influenced
by its tolerogenic features. However, hepatic tolerance is
not absolute since protective immunity can be triggered.
Our goal was to define how to deliberately elicit an
intrahepatic protective immune response. To achieve this,
we purified immune cells residing in the vascular bed of
human livers and we probed their reactivity against
different pathogen-associated molecules, mimicking sig-
nature components of viruses or bacteria. We found that
robust production of anti-viral cytokine IFN-c was induced
only by the TLR8 agonist ssRNA40. Mechanistically,
ssRNA40 triggered hepatic monocytes to produce IL-12
and IL-18 cytokines, which stimulated IFN-c production by
liver-resident CD161Bright MAIT and CD56Bright NK cells. We
also demonstrated that ssRNA40-mediated activation
could occur in pathologic (HBV- or HCV-chronically
infected) livers and that a similar cytokine-mediated
activation of intrahepatic cells could also be triggered
upon bacterial infection. Thus, we showed that the liver
immune cells can respond vigorously to specific pathogen-
associated molecules. The selective production of IFN-c by
liver-resident cells could have therapeutic implications for
the treatment of chronic liver infections.
TLR-8 Mediated Activation of Intrahepatic Innate Cells
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liver or blood (Fig. 2C second panel) and their capacity to produce
IFN-c, measured by geometric MFI (Fig. 2C third panel) were not
different in relation to their anatomical origin. Therefore, the
higher production of IFN-c in the supernatant of ssRNA40-
stimulated LDCs in comparison to PBMCs is likely a consequence
of the specific enrichment of MAIT and NKBright cells in the
hepatic environment.
Characterization of ssRNA40-mediated activation of
intrahepatic immune cells
We conducted a series of experiments to characterize the
mechanism of ssRNA40-mediated activation of intrahepatic
immune cells. We first blocked the generation of endolysosomes
that are necessary for TLR8 signaling upon ssRNA40 stimulation
[9] by using the endosomal acidification inhibitor chloroquine and
the vacuolar-type H+ ATPase inhibitor bafilomycin A1. The
experiments demonstrated that inhibition of endolysosome acid-
ification indeed blocked ssRNA40-mediated activation (Fig. S1),
confirming the essential role of TLR8 in ssRNA40 stimulation. We
also confirmed that the production of IFN-c was dependent on
uracil-rich ssRNA40, but not seen with its control, adenine-rich
ssRNA41 [10], or its vehicle, Lyovec (Fig. S2).
We next analyzed how ssRNA40 activates MAIT and NKBright
cells. A previous study of hepatic NK-cell activation demonstrated
that IL-18 and IL-12p70 (hereby stated as IL-12) production by
hepatic monocytes is necessary for their activation [6]. MAIT cells
are instead known to be principally triggered by microbial
riboflavin metabolites presented by MR1 molecules on APCs
[11], even though recent studies by others [12] and us [13]
indicated that upon overnight co-culture with bacteria, circulating
MAIT-cell activation was dependent on the MR1 recognition as
well as on the presence of IL-12 and IL-18. We therefore analyzed
the role played by IL-12 and IL-18 in the ssRNA40-mediated
activation of intrahepatic lymphocytes. LDCs from three different
donors were stimulated with ssRNA40 in the presence or absence
of anti-IL-12 or anti-IL-18 neutralizing antibodies. Anti-IL-12 or
anti-IL-18 antibodies inhibited activation of hepatic MAIT and
NK cells (Fig. 3A). Furthermore, addition of recombinant IL-12
and IL-18 to LDCs induced IFN-c production selectively in
MAIT, NKBright and also cd T cells, similarly to what observed in
ssRNA40-mediated stimulation of LDCs (Fig. 3B).
The importance of IL-12 and IL-18 cytokines in the ssRNA40-
mediated activation of intrahepatic immunity was further
supported by the observation that across all tested TLR agonists,
only ssRNA40 elicited a production of both IL-12 and IL-18
cytokines in LDCs (Fig. 3C). More importantly, ssRNA40 was the
only TLR agonist that stimulated a significantly large (mean:
824.2 pg/mL) production of IL-12 (P,0.0001).
Human monocytes, particularly the CD14dimCD16+ popula-
tion, have been shown to sense nucleic acids through TLR8
receptors [14]. We therefore directly tested whether hepatic
monocytes produce IL-12 and IL-18 upon ssRNA40 stimulation.
Hepatic monocytes were sorted from 2 different donors of LDCs
and then stimulated with ssRNA40 for 18 hours. IL-12 and IL-18
production were detected both at mRNA and protein levels
(Fig. 3D).
To directly test the ability of ssRNA40-activated monocytes to
stimulate IFN-c production by NK and MAIT cells, we sorted
different populations of APC and lymphocytes (NK and MAIT)
from one normal liver and one healthy peripheral blood.
Regardless of their anatomical origin (Fig. 3E), only monocytes
were able to stimulate IFN-c production in NK and MAIT cells.
The ability of intrahepatic and circulating monocytes to activate
NK and MAIT cells after ssRNA40 activation was further
confirmed in depletion experiments. These were performed in
cells purified in two distinct healthy liver and blood samples.
Depletion of monocytes or total APC from bulk cell populations
abolished the ssRNA40-mediated activation of MAIT and NK
cells (Fig. 3F).
Activation of hepatic MAIT cells by IL-12 and IL-18 upon
bacterial infection
We recently demonstrated that overnight bacterial stimulation
of healthy PBMCs activated MAIT cells to produce IFN-c directly
via MR1 as well as indirectly via IL-12- and IL-18-dependent
mechanisms [13]. To test if this finding was true in LDCs, we
stimulated bulk population with riboflavin- and non-riboflavin-
synthesizing bacteria (E. coli and E. faecalis respectively): only
riboflavin-synthesizing bacteria can produce a ligand presented by
MR1 [11]. The bacterial stimulation was performed for 20 hours
in the presence or absence of blocking antibodies against MR1 or
IL-12 and IL-18. Importantly, we observed that upon overnight
co-culture with riboflavin-synthesizing bacteria, hepatic MAIT
cells were activated by both IL-12 and IL-18 cytokines and by
MR1-restricted ligand (Fig. 4A and 4B). In contrast, activation by
non-riboflavin-synthesizing bacteria was entirely dependent upon
IL-12 and IL-18. Similar results were obtained using THP1 cells, a
monocytic cell line, as APCs. Consistent with our findings with
blood-derived MAIT cells [13], early activation (5 hours) of liver-
derived MAIT cells with riboflavin-synthesizing bacteria was
MR1-dependent, while later activation (20 hours) was dependent
upon both MR1 and IL-12 and IL-18 (Fig. S3). Similarly,
experiments using non-riboflavin-synthesizing bacteria reinforced
the important role of cytokines in MAIT-cell activation to produce
IFN-c.
Activation of hepatic MAIT cells by ssRNA40 mimics
MAIT-cell activation upon bacterial infection
To further analyze whether TLR8-mediated activation mimics
bacterial stimulation in the intra-hepatic environment, we pulsed
LDCs with ssRNA40, riboflavin-synthesizing bacteria (P. aerugi-
nosa), anti-CD3/CD28-coupled beads or PMA/Ionomycin and
characterized cytokines produced by hepatic MAIT cells after
overnight incubation. Fig. 5 shows that ssRNA40 elicited a
cytokine profile in intrahepatic MAIT cells similar to that induced
upon bacterial infection, but different to those obtained by anti-
CD3/CD28-coupled beads or PMA/Ionomycin. MAIT cells
Figure 1. Selective stimulation of liver-derived cells by a TLR8 agonist. (A) Pie charts depict the average proportion of different subsets of
lymphocytes, monocytes and dendritic cells found in the liver (n = 6) and in the peripheral blood (n = 7) of healthy donors. (B) Mean6SD total
concentration of cytokines (IFN-a, IFN-c, TNF-a, IL-1b, IL-6, IL-17a and IL-10) in the supernatant after stimulation of purified lymphocytes isolated from
the peripheral blood (n = 5) and liver (n = 9) with the indicated TLR agonist and anti-CD3/CD28-coupled beads. Unstimulated lymphocytes were used
to determine the background levels and the background subtracted values are displayed. (C) Background subtracted Mean6SD concentrations of
individual cytokines quantified in the supernatant of purified lymphocytes isolated from the peripheral blood (n = 5) or liver (n = 9) and stimulated
with either TLR8, TLR7 or TLR4 agonist or anti-CD3/CD28-coupled beads. (D) Heatmap shows the background subtracted mean concentrations of IFN-
c in the supernatants of blood (n = 5) or liver- derived lymphocytes (n = 9) stimulated with the indicated TLR agonist. * and ** indicates P,0.05 and
P,0.01 respectively.
doi:10.1371/journal.ppat.1004210.g001
TLR-8 Mediated Activation of Intrahepatic Innate Cells
PLOS Pathogens | www.plospathogens.org 4 June 2014 | Volume 10 | Issue 6 | e1004210
TLR-8 Mediated Activation of Intrahepatic Innate Cells
PLOS Pathogens | www.plospathogens.org 5 June 2014 | Volume 10 | Issue 6 | e1004210
exclusively produced IFN-c without a concomitant major
production of TNF-a (Fig. 5) or IL-17A (not shown) when
stimulated with ssRNA40 or bacteria. In contrast, significant
proportions of TNF-a mono-producers and IFN-c/TNF-a double
producers were observed only when MAIT cells were stimulated
with anti-CD3/CD28-coupled beads or PMA/Ionomycin. Taken
together, ssRNA40 induced an intrahepatic immune response that
resembles the one triggered by bacterial infection.
TLR8-activated immune response in diseased livers
The demonstration that a TLR8 agonist, through production of
IL-12 and IL-18 from intrahepatic monocytes, stimulated a robust
production of IFN-c in liver resident lymphocytes could have
therapeutic implications. In HBV transgenic mice, for example,
IL-12 and IL-18 treatment causes an inhibition of HBV
replication that was mediated by IFN-c production from NK
and NKT cells [15,16]. However, pathological processes can alter
the cellular composition and the cytokine milieu of the liver
microenvironment which can result in the inhibition of T- and
NK-cell function [17]. A recent characterization of the immuno-
logical profile in chimpanzees treated with an oral TLR7 agonist
has for example shown a reduced cytokine and chemokine
production in chronic HBV-infected animals in comparison to the
healthy ones [18]. We therefore tested whether liver pathological
processes can alter the ability of TLR8 agonist to activate
intrahepatic immunity.
The limited number of cells obtained in diagnostic liver biopsies
is insufficient to perform any functional analysis. Thus we purified
hepatic immune cells from HBV- or HCV-associated liver
explants due to the end-stage liver disease following the identical
cold perfusion method applied for healthy livers. In all cases, the
pathological processes were very advanced, i.e., either cirrhosis or
hepatocellular carcinoma. The functionality of the sorted whole
monocytes from pathological liver explants to respond to ssRNA40
stimulation was first evaluated at protein (4 pathologic livers) and
mRNA (5 pathologic livers) levels. Upon ssRNA40 overnight
stimulation, pathological liver-derived monocytes were able to
produce IL-12 and IL-18 cytokines. The cytokine concentrations
in pathological livers were slightly higher than observed in healthy
livers, even though they didn’t reach statistical significance
(Fig. 6A).
We next tested the ability of pathological LDCs to produce IFN-
c after ssRNA40 stimulation. Intracellular analysis of IFN-c
production confirmed that also in responding pathological livers,
MAIT and NKBright cells were the major IFN-c-producing innate
immune cells (Fig. 6B). In most of the LDCs of pathological livers
(5 out of 7), ssRNA40 stimulated IFN-c production from viable
intrahepatic lymphocytes even though to levels lower than those
observed in healthy LDCs (mean6SD: 129261957 vs
497563948, P= 0.0311; Fig. 6C). Taken together, these data
show that ssRNA40 can mediate activation of intrahepatic
immunity also in livers with advanced pathological process.
Since the lower IFN-c quantity detected in the advanced
pathological livers might be a direct consequence of the low
intrahepatic frequencies of cells responding to ssRNA40, we
characterized the composition of liver-derived cells in samples
from both end-stage liver diseases and in less advanced liver
pathologies, such as chronic hepatitis B. In the latter, low cell
numbers have severely limited our analysis only to the frequencies
of MAIT cells.
Among the major ssRNA40-responding cells (MAIT, cd T and
NK cells), patients with end-stage liver disease have a significantly
lower frequency of MAIT cells compared to healthy subjects
(Fig. 6D). In addition, a viable population of monocytes were
clearly detectable in LDCs purified from pathological livers with
the only difference being an increased frequency of CD16+
monocytes (comprising both CD14+CD16+ and CD14dimCD16+
subsets) in pathological compared to healthy livers (15.3% vs 5.5%
of total CD45+HLA-DR+ cells; P = 0.05), confirming previous
results obtained in chronic hepatitis [19].
MAIT cells were, similar to NKBright cells [20], enriched in the
liver compartment of untreated CHB patients and, unlike in end-
stage liver disease, hepatic MAIT-cell frequency remains similar to
that found in healthy subjects (Fig. 6E). Thus, the intrahepatic
innate lymphocyte population is relatively conserved at least in
chronic HBV-infected livers and might be potentially triggered by
ssRNA40 stimulation.
Discussion
We demonstrate here that the human liver environment is
specifically equipped with a network of innate immune cells
(monocytes, MAIT and NKBright cells), which is not intrinsically
tolerant or hyporesponsive. On the contrary, this cellular network
can sense distinct pathogen-associated molecules and can generate
a robust immune response. We show that substantial intrahepatic
production of IFN-c is preferentially activated in LDCs by the
TLR8 agonist ssRNA40 and we identified CD161Bright MAIT and
NKBright cells as the principal liver-resident IFN-c-producing
lymphocytes. We also show that their activation is mediated by IL-
12 and IL-18 produced by the TLR8-activated hepatic monocytes.
The demonstration that intrahepatic immune cells were strongly
activated by ssRNA40, but not by exposure to LPS, flagellin or
other bacterial products, shows that the immune cells residing
within the liver vascular system modulate their immunological
responses to different pathogen-associated molecules [3]. In this
context the TCR specificity of the MAIT cells is not critical and
indeed the CD161Bright CD8+ T-cell population as a whole, of
which the MAIT cells are the key subset, possesses the innate
feature to preferentially respond to cytokine-mediated stimulation
[13].
Even though TLR8-mediated recognition has been associated
with viral infections, new findings link TLR8 sensing to viable
bacterial infection [21,22] and unmodified RNAs, a hallmark of
viable bacteria [23,24]. We might therefore hypothesize that the
strong activation of intrahepatic immunity selectively triggered by
TLR8 agonist reflects the ability of intrahepatic cells - in particular
MAIT cells well known for their antimicrobial capability [25] - to
Figure 2. Characterization of intrahepatic immune cell subsets that produce IFN-c upon TLR8 agonist stimulation. (A) The left panel
shows a tree plot depicting lymphocyte subsets within the healthy liver compartment that produce IFN-c upon ssRNA40 stimulation. A
representative donor, LP1, is presented. Pie charts illustrate the same data from 4 healthy donors, LP1-LP4. (B) Production of IFN-c, TNF-a and IL-1b by
seven immune cell subsets within the liver compartment upon ssRNA40 stimulation. The frequency of cytokine-producing cells within each subset is
shown in the quadrants. Representative contour plots of one healthy donor are presented. (C) Analysis of IFN-c production by MAIT and NKBright cells
within the peripheral blood (n = 3) and liver (n = 4) compartments of healthy donors. The left panel illustrates the frequency of MAIT or NKBright cells
represented as a proportion of total viable lymphocytes in each compartment. The middle panel shows the frequency of IFN-c-producing MAIT or
NKBright cells in each compartment. The right panel shows the production of IFN-c per cell within the MAIT or NKBright populations in each
compartment. Values are displayed as mean6SD. * and n.s. indicate P,0.05 and P.0.05, respectively.
doi:10.1371/journal.ppat.1004210.g002
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control active bacterial infection while ignoring intestinal floral
products that leak into the intrahepatic blood circulation. The
strong activation of intrahepatic immunity observed in our
experiments utilizing three different bacteria strains (P. aeruginosa,
E. coli and E. faecalis) further support such an hypothesis.
Nevertheless, our data might indicate that TLR8-mediated
activation of intrahepatic immunity might also take place during
other pathological conditions, e.g., acute viral hepatitis and
hepatic flares during chronic viral hepatitis. Unmodified RNAs,
the possible trigger of TLR8-mediated immune response, are also
highly enriched within mitochondria and as such can be released
during flares when cells are damaged or die [23]. In this context,
our observation that ssRNA40-mediated activation could be
detected in pathologic liver-derived cells suggests that the
ssRNA40-generated immune response can be induced during
chronic viral infection even though the impact of hepatotropic
viruses on the TLR8-mediated activation of intrahepatic immunity
requires more in depth analysis. At the moment, our attempts to
activate hepatic MAIT cells (as well as NKBright) by exposing
LDCs to purified HBV virions (unpublished results) have been
unsuccessful.
Irrespective of their biological role during infections, the
network of innate immune cells able to respond to TLR8 agonist
within the liver sinusoids can open new therapeutic opportunities.
TLR7 agonists are the most studied TLR agonists for the
treatment of liver pathologies [18,26] due to their ability to
suppress HCV replication in hepatocytes [27] and stimulate robust
IFN-a production in plasmacytoid dendritic cells [28]. However,
our data shows that a TLR8 agonist could be advantageous for
liver-specific treatment as such an agonist preferentially activates
innate immune cells within the liver compartment while TLR7
agonists do not display any preference and do not induce robust
IL-12 and IFN-c production. The selective liver-localized
production of IFN-c could exert an efficient antiviral effect, as
HBV clearance was shown to be mediated by IFN-c in infected
chimpanzees [29] and HBV transgenic mice [30]. In this respect it
is important to note that the recent demonstration of therapeutic
efficacy in HBV-infected chimpanzees of a novel synthetic TLR
agonist (GS-9620; labeled as a TLR7 agonist) was not only
associated with serum detection of IFN-a, but also of increased IL-
12 and CXCL10 levels [18]. Such a cytokine/chemokine profile is
also consistent with a TLR8-mediated response and can be
explained by the TLR7/TLR8 degeneracy of this synthetic
compound at high doses [31].
In addition to its ability to activate NKBright and MAIT cells, IL-
12 production following TLR8 activation might have other
immunomodulatory effects, since IL-12 can induce partial
functional recovery of exhausted HBV-specific CD8+ T cells
[32]. This concept is also supported by data from a murine model
of persistent HBV infection where single-stranded RNA could
reverse immune tolerance [33].
On the other hand, the robust activation of intrahepatic cellular
immunity via TLR8 needs to be tightly controlled, both during
natural infection or if a TLR8 agonist is to be exploited for therapy
of chronic viral infections. IFN-c is not only an antiviral cytokine
but also further induces production of inflammatory chemokines,
e.g., CXCL10, by hepatocytes [34]. CXCL10 can induce rapid
recruitment of circulating memory T cells into solid organs [35]
but can also aggravate inflammatory events that may lead to
severe liver damage [36]. In this respect, the balance between
protective or damaging effects of intrahepatic innate immune-cell
activation will have to be carefully evaluated in vivo.
In conclusion, we demonstrate that a network of hepatic innate
immune cells responds to TLR8-mediated activation by inducing
a potent immune response. The strategic positioning of such cells
in the liver can constitute an advantage to immediately sense and
control the presence of viable bacteria in the gastrointestinal
circulation and might also open new therapeutic options for the
treatment of different liver diseases.
Materials and Methods
Human samples
Collection of healthy human LDCs (n = 24) and PBMCs (n= 7)
was performed as previously reported [8]. Due to ethical
considerations, immune cells derived from healthy liver donors
were instead compared to those of age-matched healthy donors of
PBMCs [8]. Liver biopsies were performed on untreated chronic
HBV-infected/CHB patients (n = 13). These biopsies were cul-
tured in medium for 24 hours to gently release mononuclear cells,
(‘walk-out’ method) [37]. Cell viability collected using this method
exceeded 80%. Among these CHB patients, 10 subjects donated
blood as well, from which PBMCs were collected. Mononuclear
cells were also collected from HBV/HCV-related liver explants
due to end-stage liver disease through perfusion using cold buffer
solution (n= 6).
Ethics statement
All participants in this study are adults. The study was approved
by the local ethical boards of the Asian American Liver Centre
and the Royal London Hospital and all participants gave written
informed consent.
Antibodies and reagents
Monoclonal antibodies of anti-human-CD3-eFluor605NC (clone
OKT3) or –FITC or PE-Cy7 (UCHT1), anti-CD4-eFluor650NC
Figure 3. TLR8 agonist activation of liver-derived cells were mediated by IL-12 and IL-18 production from monocytes. (A) Frequency
of IFN-c-producing MAIT and NKBright cells were quantified after stimulation of liver-derived lymphocytes (n = 3) with TLR8 agonist in the absence or
presence of IL-12 or IL-18-neutralizing antibodies/proteins. The IFN-c response was normalized to the isotype control. Bars show the mean response
while the individual values were indicated by the symbols. (B) Frequency of IFN-c producing cells within each indicated subset were quantified after
stimulation of liver derived lymphocytes (n = 2) with recombinant human IL-12 and IL-18. (C) Mean6SD concentrations of IL-12p70 (n = 9) and IL-18
(n = 3) in the supernatants of liver derived lymphocytes after stimulation with the indicated TLR agonists. IL12p70 was significantly increased after
ssRNA40 stimulation (p,0.0001). (D) Quantification of IL-12p35, IL-12p40 and IL-18 mRNA levels in sorted hepatic monocytes (n = 2) before and after
stimulation with ssRNA40. The corresponding background subtracted supernatant concentrations of IL-12 and IL-18 were also quantified and
displayed as grey bars. Error bars show the standard deviation of our data set. (E) MAIT cells from the liver or blood were sorted and stimulated with
ssRNA40 in the presence or absence of a single subset of autologous and sorted APC (monocytes, B cells, mDC or pDC). Dot plots show the frequency
of IFN-c-producing liver-derived MAIT cells before and after stimulation with ssRNA40 in the presence of the indicated APC subset. The bar chart
compares the APC requirement of ssRNA40 stimulated blood- and liver-derived MAIT cells. The frequency of IFN-c-producing MAIT cells is normalized
to that in the presence of monocytes. (F) Blood- or liver-derived lymphocytes were stimulated with ssRNA40 after depletion of either APCs (HLA-DR
positive) or monocytes. Background subtracted frequency of IFN-c-producing MAIT and NKBright cells from each donor are shown as bars. Values are
normalized to that in the absence of depletion.
doi:10.1371/journal.ppat.1004210.g003
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(RPA-T4), anti-CD7-FITC (4H9), anti-CD161-PerCP-Cy5.5
(HP-3G10), anti-HLA-DR-AlexaFluor700 (LN3) were obtained
from eBioscience (San Diego, CA). Anti-CD8-V500 (RPA-T8),
anti-CD14-PE-Cy7 (M5E2), anti-CD45-V500 (HI30), anti-
CD56-PE-Cy7 (B159), anti-IFN-c-V450 (B27), anti-TNF-a-
APC (6401.1111) antibodies were obtained from Becton
Dickinson (BD, San Jose, CA). Anti-CD16-APC-Cy7 (3G8),
anti-CD19-FITC (HIB19), anti-CD20-FITC (2H7), anti-CD56-
FITC or APC-Cy7 (HCD56), anti-Va7.2 TCR-PE or -APC
(3C10) antibodies were obtained from Biolegend (San Diego,
CA). Anti-CD161-APC (191B8) and IFN-c-FITC (45-15)
antibodies were obtained from Miltenyi Biotec (UK). Anti-
TCRcd-FITC or -PE (5A6.E9) antibody and Live/Dead Fixable
Dead Cell Stain Kit (yellow) were obtained from Invitrogen
(Carlsbad, CA). Agonists for human TLR1/2 (Pam3CSK4;
1 mg/mL), TLR2 (HKLM; 108cells/mL), TLR2/6 (FSL-1;
1 mg/mL), TLR3 (Poly(I:C); 10 mg/mL), TLR4 (E. coli K12
LPS; 1 mg/mL), TLR5 (S. typhimurium flagellin; 1 mg/mL), TLR7
(Imiquimod; 5 mg/mL), TLR8 (ssRNA40; 1 mg/mL or otherwise
stated) and TLR9 (CpG ODN2216; 5 mM) were obtained from
Invivogen (San Diego, CA). Anti-CD3/CD28-coupled beads
were obtained from Invitrogen (1:1 bead-to-cell ratio). Brefeldin
A (2 mg/mL for overnight incubation or otherwise stated),
bafilomycin A1 (10 nM), chloroquine diphosphate (5 mg/mL),
PMA (2 ng/mL) and Ionomycin (1 mg/mL) were obtained from
Sigma-Aldrich (Saint Louis, Missouri).
Quantification of secreted cytokines
LDCs or PBMCs were plated at 100,000 cells per well in 96-
well plates and stimulated with TLR agonists or anti-CD3/CD28-
coupled beads for 18 hours. Sorted monocytes were plated at
150,000 cells per well in 96-well plates and stimulated with
Figure 4. Activation of MAIT cells upon overnight bacterial infection. (A) Representative dot plots from one healthy donor of IFN-c
production by liver-derived MAIT cells upon co-culture for 20 hours with bacteria which synthesize riboflavin (Escherichia coli) or bacteria which do
not synthesize riboflavin (Enterococcus faecalis) in the presence or absence of blocking antibodies against MR1 and/or IL-12 and IL-18. (B) The
frequency of IFN-c-producing MAIT cells when co-cultured with either riboflavin-synthesizing or non-riboflavin-synthesizing bacteria in the presence
of blocking antibody is given relative to that in the absence of any blocking antibody, the latter of which is set as 1. Three healthy donors were tested
with each symbol representing one donor.
doi:10.1371/journal.ppat.1004210.g004
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ssRNA40 for 18 hours. Supernatant was collected subsequently
and cytokine concentrations were assessed via cytokine
multiplex bead-based assay according to the manufacturer’s
instructions (Luminex, Austin, TX). ELISA of IL-18 was
performed according to the manufacturer’s instructions (R&D
Systems).
Flow cytometry
The experiment was performed as previously reported [8]. Data
was analysed using FACSDiva (BD), FlowJo (Tree Star) or Kaluza
(Beckman Coulter) software.
Cell sorting and depletion
Hepatic MAIT cells were sorted as previously reported [8].
Subsets of hepatic lineage positive (CD3+CD7+CD56+) and
antigen-presenting cells (CD32CD72CD562HLA-DR+) were
sorted using a BD FACS Aria. Subsets of hepatic APCs were
subsequently sorted based on the expression of CD14++ and
CD16+ (monocytes), CD20+ (B cells), CD11c+ (mDCs) or
CD123+ (pDCs). Pan monocytes were depleted from the
bulk population using the pan monocyte isolation kit (Miltenyi
Biotec).
Direct co-culture assay
Sorted hepatic lineage positive cells were co-cultured with
sorted APCs at an effector-to-target (E:T) ratio of 1:4 in the
presence of ssRNA40 overnight with addition of brefeldin A
(10 mg/mL) in the final 5 hours. The intracellular production of
IFN-c was assessed by staining and FACS as above.
Blockade of MR1 or of IL-12 and IL-18 upon ssRNA40
stimulation
LDCs or PBMCs were stimulated with ssRNA40 overnight in
the presence of anti-MR1 monoclonal antibody at 10 mg/mL
(clone 26.5, kindly provided by Ted. H. Hansen). Alternatively,
the stimulated cells were cultured in the presence of anti-IL-12p70
monoclonal antibody (clone 24910) or rhIL-18 binding protein
(clone 136007) at concentration 20 mg/mL (R&D Systems).
Brefeldin A (10 mg/mL) was added in the final 5 hours. The
intracellular production of IFN-c was determined by flow
cytometry.
Bacterial stimulation of MAIT cells
The bulk population of liver-derived cells was stimulated
overnight with two groups of bacteria, i.e., the ones that synthesize
riboflavin (Escherichia coli or Pseudomonas aeruginosa) and the one that
does not (Enterococcus faecalis). Two million paraformaldehyde-fixed
E. coli or E. faecalis were added for 20 hours in the presence or
absence of blocking antibodies against IL-12p70 (R&D
Systems) and IL-18 (MBL International, USA) at concentra-
tion 5 mg/mL or against MR1 (10 mg/mL) as indicated.
Alternatively, to characterize the early and late activation of
MAIT cells, THP1 cell line was used as APCs. To assess the
cytokine produced by MAIT cells upon infection with
riboflavin-synthesizing bacteria, viable P. aeruginosa was added
overnight at MOI 10 per monocyte. Brefeldin A (10 mg/mL)
was added for the final 4–5 hours of culture. Intracellular
cytokine staining was performed to detect production of IFN-c
and TNF-a by MAIT cells.
Figure 5. TLR8 stimulation mimics MAIT cell activation upon bacterial infection. (Upper panels) Representative contour plots illustrate the
production of IFN-c and TNF-a by MAIT cells upon overnight stimulation of liver-derived cells with ssRNA40 (5 mg/mL), riboflavin-synthesizing
bacteria (Pseudomonas aeruginosa), anti-CD3/CD28-coupled beads or PMA/Ionomycin. (Lower panels) Pie charts depicting the proportion of IFN-c or
TNF-a monoproducers and IFN-c/TNF-a double producers among activated MAIT cells are shown. Data expressed as means obtained from two
healthy donors.
doi:10.1371/journal.ppat.1004210.g005
TLR-8 Mediated Activation of Intrahepatic Innate Cells
PLOS Pathogens | www.plospathogens.org 10 June 2014 | Volume 10 | Issue 6 | e1004210
TLR-8 Mediated Activation of Intrahepatic Innate Cells
PLOS Pathogens | www.plospathogens.org 11 June 2014 | Volume 10 | Issue 6 | e1004210
Statistical analysis
The nonparametric Mann-Whitney U test was used to
determine the statistical significance of differences.
Supporting Information
Figure S1 IFN-c and TNF-a production by MAIT cells upon
ssRNA40 stimulation in the presence or absence of chloroquine or
bafilomycin A1.
(TIF)
Figure S2 Frequency of IFN-c-producing cells within MAIT
cells upon activation with ssRNA40/Lyovec, ssRNA41/Lyovec, or
Lyovec alone at 1 mg/mL (n= 3; mean6SEM; * indicates P,
0.05).
(TIF)
Figure S3 Early and late activation of liver-derived MAIT cells
by riboflavin-synthesizing and non-riboflavin-synthesizing bacte-
ria. THP1 cells were incubated overnight with E. coli or E. faecalis.
Liver-derived cells were either added for the final 5 hours of
incubation (A and B) or were co-cultured overnight (C and D). The
frequency of IFN-c-producing MAIT cells (A and C) and the ratio
of the frequency of IFN-c-producing MAIT cells in the presence of
blocking antibody to that in the absence of any blocking antibody
are displayed (B and D; n = 3; each symbol represents one donor).
The frequency of IFN-c-producing MAIT cells upon bacterial
infection without any blocking antibodies was set as 1.
(TIF)
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